Issue 119

harmful gambling

Psychedelic-assisted therapy for harmful gambling

Tryp Therapeutics recently announced interim results from its Phase II trial with psilocybin in the treatment of binge eating disorder, with daily binge eating episodes reduced by an average of 80%.

The UK is home to one of the largest gambling markets in the world, generating £14 billion in profit in 2020. For many, it is seen as harmless entertainment, but for others it can become a serious problem.

The socioeconomic costs associated with harmful gambling have been estimated at £1.5 billion, with disadvantaged groups most susceptible to problem gambling.

Psychedelic-assisted therapy is increasingly being studied in the treatment of behavioural addictions, with UK-based Awakn Life Sciences conducting the first-ever study investigating ketamine as a treatment for gambling disorder.

READ MORE

EU REGULATORS PROMOTE POTENTIAL OF PSYCHEDELIC-ASSISTED THERAPIES

The governing bodies highlight the socioeconomic benefits of innovative treatments for mental health conditions.

Read More

PAREA PUSHES FOR ACCESS TO PSYCHEDELIC HEALTHCARE IN EUROPE

Psychedelic Health spoke with Tadeusz Hawrot, Founder of the Psychedelic Access and Research European Alliance.

Read More

BUSINESS AND INVESTMENT

Cybin announces financial results for Q4 2022.

Reunion Neuroscience reports Q4 2022 fiscal results.

Ad campaign for psilocybin access launches in the UK.

Potential health risks with psychedelic-assisted therapy.

Bright Minds Biosciences to be delisted from NASDAQ.

The scheduling of psychedelic medicines in Europe.

The future of psychedelic healthcare in the United States.

The medical potential of psilocybin-assisted therapy.

Increased interest in the therapeutic use of mescaline.

On Thursday, 6 July, industry leaders will converge at the iconic British Museum for PSYCH Symposium: London 2023.

Early Bird tickets on sale for £299 + VAT.

TICKET REGISTRATION

SCIENCE AND RESEARCH

Psychedelic research themes in 2022.

Psychedelic medicines and impairments in social functioning.

With contributions from Awakn, Cybin and Psyence, The Psychedelics as Medicine Report: Fourth Edition empowers investors to make informed decisions.

COMPLIMENTARY DOWNLOAD

REGULATION AND LEGISLATION

The decriminalisation of psychedelic medicine.

Arizona lawmakers approve psilocybin research bill.

Hawaii senators approve bill to study psychedelic medicine.

Canadian MPs support calls to expand access to psychedelic-assisted therapy.

Would your organisation benefit from engaging with Europe’s psychedelic medicine community?

Event partnership provides the opportunity to engage with an audience ready to support the development of psychedelic healthcare.

Previous partners include COMPASS Pathways, Beckley Psytech and Awakn Life Sciences.

PARTNERSHIP OPPORTUNITIES

ARTICLES OF INTEREST

Lion’s Mane may improve brain cell growth.

How social media affects teenagers’ mental health.

Nurses’ mental health at lowest point since pandemic.

Do you know a spokesperson who could provide insights on the future of psychedelic healthcare?

Previous symposium speakers include:

  • Rick Doblin – Founder, MAPS
  • Cosmo Feilding Mellen – CEO, Beckley Psytech
  • Carol Routledge – Chief Medical and Scientific Officer, Small Pharma
  • MP Crispin Blunt – Chair, The Conservative Drug Policy Reform Group
SPEAKING OPPORTUNITIES
Partner with us